Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
New omicron subvariants are rising in U.S., and FDA panel gives its backing to Novavax vaccine
10:25am, Thursday, 09'th Jun 2022 MarketWatch
The BA.4 and BA.5 subvariants of the highly transmissible omicron variant of the coronavirus that causes COVID-19 are spreading rapidly, according to data from the Centers for Disease Control and Prev
U.S. prepares to distribute Covid-19 shots to children under 5
09:42am, Thursday, 09'th Jun 2022 MarketWatch
The Biden administration is gearing up to roll out vaccines for children under age 5 in conjunction with educational and outreach efforts, if the shots are approved by federal regulators.
Cathie Wood Trims Pfizer Stake And Loads Up $25M In Rival COVID-19 Vaccine Maker
04:01am, Thursday, 09'th Jun 2022 Benzinga
Cathie Wood led Ark Invest on Wednesday initiated a position in Moderna Inc (NASDAQ: MRNA) after the biotech company said an updated version of its COVID-19 booster vaccine appeared to provide
Pfizer (PFE) Stock Moves -0.91%: What You Should Know
09:45pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
In the latest trading session, Pfizer (PFE) closed at $53.47, marking a -0.91% move from the previous day.
HC Wainwright Says Non-mRNA COVID-19 Option Underappreciated
06:57pm, Wednesday, 08'th Jun 2022 Benzinga
HC Wainwright says safety concerns were noted for Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine, but the strength of data showed that benefit outweighs risks.
With a 21-0 vote (one abstention) fo
FDA Committee Proposes EUA Nod to Novavax's (NVAX) COVID Jab
05:21pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
An FDA advisory committee supports granting emergency use authorization to Novavax's (NVAX) COVID-19 vaccine for use in adults. Post the news, the stock rallies 20% in pre-market trading.
COVID patients with weak immune systems should get priority care to avoid new variants emerging, experts say
03:10pm, Wednesday, 08'th Jun 2022 MarketWatch
Patients suffering from long-term symptoms of COVID-19 because they are immunocompromised should be prioritized for treatments because some variants have emerged in people who struggle to eliminate in
Novavax Won a Nod From FDA Advisors. Now What?
03:00pm, Wednesday, 08'th Jun 2022 The Motley Fool
An FDA decision may come in a matter of days.
COVID patients with weak immune systems should get priority care to avoid new variants emerging, experts say
11:47am, Wednesday, 08'th Jun 2022 MarketWatch
Patients suffering from long-term symptoms of COVID-19 because they are immunocompromised should be prioritized for treatments because some variants have emerged in people who struggle to eliminate in
Intercept (ICPT) Announces Delay in Meeting With the FDA
02:06pm, Tuesday, 07'th Jun 2022 Zacks Investment Research
Intercept (ICPT) faces yet another setback as its resubmission for NDA for OCA for NASH gets delayed.
A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street
09:28am, Tuesday, 07'th Jun 2022 Benzinga
Pre-open movers
U.S. stock futures traded lower in early pre-market trade after closing slightly higher in the previous session. Investors are awaiting earnings results from United Natural Foods, Inc
Pfizer To Boost Production Of Oral COVID-19 Pill With $120M Michigan Investment
08:18am, Tuesday, 07'th Jun 2022 Benzinga
Pfizer, Inc. (NYSE: PFE) is upping its commitment to manufacture its oral COVID-19 pill Paxlovid in the United States.
What Happened: Pfizer will invest an incremental $120 million at its Kalamazoo
Novavax (NVAX) Down After FDA Raises Concern for Its COVID Jab
05:59pm, Monday, 06'th Jun 2022 Zacks Investment Research
Before deciding the fate of Novavax's (NVAX) COVID-19 vaccine, a document issued by the FDA suggests that the vaccine may cause heart problems like myocarditis/pericarditis.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
01:00pm, Monday, 06'th Jun 2022 Zacks Investment Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
2 Bruised Dividend Stocks to Buy While They're Cheap
12:15pm, Monday, 06'th Jun 2022 The Motley Fool
Lower share prices won't stop them from hiking their dividends.
